PE20221316A1 - Proteinas que se unen a nkg2d, cd16 y flt3 - Google Patents

Proteinas que se unen a nkg2d, cd16 y flt3

Info

Publication number
PE20221316A1
PE20221316A1 PE2022000621A PE2022000621A PE20221316A1 PE 20221316 A1 PE20221316 A1 PE 20221316A1 PE 2022000621 A PE2022000621 A PE 2022000621A PE 2022000621 A PE2022000621 A PE 2022000621A PE 20221316 A1 PE20221316 A1 PE 20221316A1
Authority
PE
Peru
Prior art keywords
flt3
proteins
binding site
antigen
binds
Prior art date
Application number
PE2022000621A
Other languages
English (en)
Inventor
Hemanta Baruah
Gregory P Chang
Ann F Cheung
Asya Grinberg
Zong Sean Juo
Thomas J Mcquade
Daniel Fallon
William Haney
Steven O'neil
Ronnie Wei
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of PE20221316A1 publication Critical patent/PE20221316A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

SE REFIERE A UNA PROTEINA QUE COMPRENDE (a) UN PRIMER SITIO DE UNION A ANTIGENO QUE SE UNE A NKG2D; (b) UN SEGUNDO SITIO DE UNION A ANTIGENO QUE SE UNE A FLT3; Y (c) UN DOMINIO FC DE ANTICUERPO O UNA PORCION DEL MISMO SUFICIENTE PARA UNIRSE A CD16, O UN TERCER SITIO DE UNION A ANTIGENO QUE SE UNE A CD16; EN DONDE CADA (a), (b) Y (c) SE ENCUENTRAN DEFINIDOS A TRAVES DE LA SECUENCIA AMINOACIDICA DE SUS CDRS DE LA REGION VARIABLE DE CADENA PESADA Y LIGERA.
PE2022000621A 2019-10-15 2020-10-14 Proteinas que se unen a nkg2d, cd16 y flt3 PE20221316A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962915123P 2019-10-15 2019-10-15
PCT/US2020/055497 WO2021076564A1 (en) 2019-10-15 2020-10-14 Proteins binding nkg2d, cd16 and flt3

Publications (1)

Publication Number Publication Date
PE20221316A1 true PE20221316A1 (es) 2022-09-07

Family

ID=75538862

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000621A PE20221316A1 (es) 2019-10-15 2020-10-14 Proteinas que se unen a nkg2d, cd16 y flt3

Country Status (16)

Country Link
US (1) US20240117054A1 (es)
EP (1) EP4045538A1 (es)
JP (1) JP2022551969A (es)
KR (1) KR20220083770A (es)
CN (1) CN115298217A (es)
AR (1) AR120223A1 (es)
AU (1) AU2020368163A1 (es)
BR (1) BR112022007128A2 (es)
CA (1) CA3153858A1 (es)
CL (1) CL2022000928A1 (es)
CO (1) CO2022004757A2 (es)
IL (1) IL292261A (es)
MX (1) MX2022004430A (es)
PE (1) PE20221316A1 (es)
TW (1) TW202128759A (es)
WO (1) WO2021076564A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
CN115925984A (zh) * 2021-08-24 2023-04-07 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
WO2023056252A1 (en) * 2021-09-29 2023-04-06 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and baff-r
WO2023107956A1 (en) * 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CA2992539A1 (en) * 2015-07-16 2017-01-19 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins
US20200165344A1 (en) * 2017-07-31 2020-05-28 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and flt3

Also Published As

Publication number Publication date
TW202128759A (zh) 2021-08-01
EP4045538A1 (en) 2022-08-24
US20240117054A1 (en) 2024-04-11
IL292261A (en) 2022-06-01
AU2020368163A1 (en) 2022-04-28
CN115298217A (zh) 2022-11-04
WO2021076564A1 (en) 2021-04-22
KR20220083770A (ko) 2022-06-20
MX2022004430A (es) 2022-07-19
CL2022000928A1 (es) 2022-10-28
CO2022004757A2 (es) 2022-09-30
BR112022007128A2 (pt) 2022-07-05
AR120223A1 (es) 2022-02-02
JP2022551969A (ja) 2022-12-14
CA3153858A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
PE20221316A1 (es) Proteinas que se unen a nkg2d, cd16 y flt3
EA202190542A1 (ru) Сконструированные биспецифические белки
CY1122053T1 (el) Ετεροδιμερικες πρωτεϊνες
EA201990331A1 (ru) Мультиспецифические антигенсвязывающие белки и способы их применения
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
CL2019002620A1 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3.
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
CO2017005388A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CL2018002034A1 (es) Proteínas de unión a antígeno que se unen a pd-l1.
EA201891322A1 (ru) Анти-tl1a/анти-tnf-альфа биспецифические антигенсвязывающие белки и их применение
EA202191457A1 (ru) Анти-pd-l1/анти-4-1bb биспецифические антитела и их применения
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
PE20200384A1 (es) Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos
AR083672A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
DOP2019000011A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
UY38803A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y usos de las mismas
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
UY37683A (es) Anticuerpo monoclonal anti-pd-l1 monoclonal
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
PE20231361A1 (es) Moleculas agonistas de union al antigeno cd28 que se dirigen a her2
EA202191231A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ
EA202190382A1 (ru) Фармацевтические составы на основе маскированных антител
CL2022000052A1 (es) Anticuerpos de pre–direccionamiento y metodos de uso